Retatrutide and diarrhoea is a clinically relevant concern for anyone following this investigational triple hormone receptor agonist. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, making it distinct from licensed agents such as semaglutide and tirzepatide. Phase 2 trial data confirm that diarrhoea is among the most frequently reported side effects, particularly during dose escalation. As retatrutide has not yet received MHRA or EMA marketing authorisation, all available evidence comes from controlled clinical trials. This article explains how common diarrhoea is, what influences its severity, and when to seek medical advice.

Retatrutide and Diarrhoea: What the Evidence Shows

Phase 2 trial data confirm diarrhoea is a common adverse effect of retatrutide, driven largely by its GLP-1 receptor agonist component, which slows gastric emptying and alters intestinal transit.

Retatrutide is an investigational triple hormone receptor agonist that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor mechanism distinguishes it from existing licensed agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist). By activating all three pathways, retatrutide produces pronounced effects on appetite suppression and metabolic regulation, but also influences gastrointestinal motility in ways that can lead to digestive side effects, including diarrhoea.

Clinical trial data from the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) confirm that diarrhoea is among the most frequently reported adverse effects associated with retatrutide. In that study, gastrointestinal symptoms — including nausea, vomiting, constipation, and diarrhoea — were reported at notably higher rates in participants receiving active treatment than in those receiving placebo, with incidence and severity broadly increasing with dose. The GLP-1 receptor agonist component is considered, based on established class effects, a likely contributor to these gastrointestinal adverse events, as GLP-1 activation slows gastric emptying and alters intestinal transit time. However, the precise contribution of each receptor pathway to gastrointestinal tolerability in a triple agonist has not been fully characterised in humans, and this attribution should be regarded as informed by class-effect data rather than confirmed mechanism.

It is important to note that retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) as of mid-2025 (regulatory status last checked June 2025). It remains under clinical investigation, and all available safety data derive from controlled trial settings rather than real-world use. The full side-effect profile may evolve as larger and longer-duration studies are completed.

How Common Is Diarrhoea During Treatment

Diarrhoea was reported in a dose-dependent manner in Phase 2 trials; at the highest doses, gastrointestinal adverse events affected over 50% of participants, with most episodes mild to moderate.

Based on Phase 2 trial data (Jastreboff et al., NEJM, 2023), diarrhoea was reported in a meaningful proportion of participants treated with retatrutide, with incidence increasing in a dose-dependent manner. Across all active-treatment groups, gastrointestinal adverse events were common; in the highest dose cohorts (up to 12 mg weekly), gastrointestinal adverse events as a composite were reported in over 50% of participants at some point during the treatment period. Diarrhoea specifically was among the most frequently cited individual symptoms, though the majority of episodes were described as mild to moderate in severity. Symptoms occurred most frequently during the dose-escalation phase and tended to diminish as participants reached and maintained their target dose.

For context, diarrhoea is reported in approximately 9–16% of patients taking semaglutide 2.4 mg (Wegovy) according to its UK Summary of Product Characteristics (SmPC, emc), and in a broadly similar range for tirzepatide (Mounjaro) per its UK SmPC. Whether the triple-agonist profile of retatrutide results in greater gastrointestinal burden than dual or single agonists has not been definitively established in head-to-head studies; any such comparison at this stage is hypothesis-generating rather than confirmed.

Key factors that may influence the likelihood and severity of diarrhoea include:

• Dose level — higher doses are associated with greater gastrointestinal burden

• Rate of dose escalation — faster titration schedules tend to worsen tolerability

• Individual gut sensitivity — those with pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS) or inflammatory bowel disease may warrant additional clinical caution, although direct evidence specific to retatrutide is not yet available; patients in these groups should discuss their suitability with a clinician before participating in any trial

• Dietary habits — high-fat or heavily spiced meals may exacerbate symptoms

Diarrhoea in this context is a pharmacological side effect, not an allergic reaction or sign of serious harm in most cases. Nevertheless, persistent or severe diarrhoea warrants clinical assessment, particularly given the risk of dehydration and electrolyte imbalance.

Managing Gastrointestinal Side Effects Safely

Smaller meals, avoiding high-fat foods, staying hydrated, and slower dose titration are the key strategies for managing retatrutide-related diarrhoea; trial participants must consult their team before taking any new medicine.

For individuals participating in clinical trials of retatrutide, or in future those prescribed it following any regulatory approval, managing gastrointestinal side effects proactively can significantly improve tolerability and treatment adherence. The following strategies are broadly recommended across incretin-based therapies and are likely to be relevant to retatrutide, though patients should always follow the specific guidance provided by their trial team or prescriber.

Dietary modifications:

• Eat smaller, more frequent meals rather than large portions

• Avoid high-fat, greasy, or heavily spiced foods, particularly during dose escalation

• Reduce alcohol intake, which can independently irritate the gastrointestinal tract

• Stay well hydrated, especially if experiencing loose stools

Lifestyle adjustments:

• Avoid lying down immediately after eating

• Allow adequate time between meals to support gastric emptying

Medication timing: Some individuals find that choosing an injection day when dietary intake can be more easily managed helps reduce the impact of acute gastrointestinal symptoms. This is a practical consideration rather than an evidence-based recommendation, and should be discussed with the prescriber or trial team.

Over-the-counter oral rehydration salts (e.g., Dioralyte) can help manage mild diarrhoea and prevent dehydration. Anti-diarrhoeal agents such as loperamide may provide short-term symptomatic relief, but should not be used if there is blood in the stool, high fever, or signs of severe dehydration, and are intended for short-term use only. Patients enrolled in a clinical trial must consult their trial team before taking any new medicine, including over-the-counter products, as this may be required by the trial protocol. Other patients should consult a pharmacist or clinician before use.

Dose reduction or slower titration is often the most effective clinical strategy when gastrointestinal side effects are persistent. In trial settings, protocol-defined dose adjustments were permitted for participants experiencing intolerable symptoms.

If you experience a suspected side effect from any medicine — including within a clinical trial — you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Trial participants should also follow their study team's reporting procedures.

When to Seek Medical Advice

Seek prompt medical attention if diarrhoea persists beyond 48–72 hours, is accompanied by blood in the stool, signs of dehydration, severe abdominal pain, or persistent vomiting.

Mild, transient diarrhoea during the early weeks of treatment with an incretin-based therapy is generally considered an expected and manageable side effect. However, there are specific circumstances in which prompt medical attention is warranted. Patients — whether enrolled in a clinical trial or, in future, receiving retatrutide through a licensed prescriber — should be clearly informed of the following red flag symptoms.

Contact your GP, trial clinician, or NHS 111 promptly if you experience:

• Diarrhoea lasting more than 48–72 hours without improvement

• Signs of dehydration, including dark urine, dizziness, dry mouth, or reduced urination

• Blood in the stool or very dark, tarry stools

• Severe or persistent abdominal pain, particularly pain radiating to the back, which may rarely indicate pancreatitis — a recognised caution across the incretin drug class

• Severe abdominal pain or cramping accompanied by fever

• Diarrhoea combined with persistent vomiting, which significantly increases dehydration risk

• Symptoms that are interfering with daily activities or sleep

Seek urgent medical attention (A&E or call 999) if:

• You are unable to keep any fluids down for more than 24 hours

• You feel faint, confused, or have a rapid heart rate alongside diarrhoea

• You develop signs of a severe allergic reaction (rash, swelling, difficulty breathing)

If you are unsure whether your symptoms require urgent attention, call NHS 111 for advice at any time.

Individuals with pre-existing conditions such as chronic kidney disease, type 1 diabetes, or inflammatory bowel disease should exercise particular caution, as dehydration and electrolyte disturbances can have more serious consequences in these groups. Older adults and those taking diuretics or other medicines affecting fluid balance should also be monitored more closely. Always inform your healthcare team of all medications you are taking, including over-the-counter remedies.

Guidance from UK Regulatory and Clinical Bodies

Retatrutide is not approved in the UK; all use must occur within MHRA-regulated clinical trials, and clinicians should refer to NICE appraisals for currently licensed weight management therapies.

As of mid-2025 (last checked June 2025), retatrutide has not been approved for clinical use in the United Kingdom. The MHRA has not granted a marketing authorisation for this agent, and it is not currently the subject of a NICE technology appraisal or clinical guideline. All use of retatrutide in the UK at present occurs within the context of regulated clinical trials, which are subject to MHRA oversight and must comply with Good Clinical Practice (GCP) standards.

The EMA similarly has not approved retatrutide for use within the European Economic Area. In the United States, the FDA has been evaluating retatrutide under an expedited development pathway for obesity; however, patients and clinicians should verify the current status directly with the trial sponsor or via ClinicalTrials.gov, as regulatory designations may change. This does not confer any approval status in the UK.

For patients and clinicians seeking guidance on currently approved weight management therapies in the UK, NICE has published relevant technology appraisals and guidelines, including:

• NICE TA875 — semaglutide (Wegovy) for weight management in adults

• NICE TA1026 — tirzepatide (Mounjaro) for weight management (please verify the current TA number and scope at nice.org.uk at the time of reading, as appraisals are subject to update)

• NICE guideline CG189 — obesity: identification, assessment and management (verify current identifier and version at nice.org.uk)

These documents provide evidence-based recommendations on patient selection, monitoring, and the management of side effects including gastrointestinal symptoms. The UK SmPCs for Wegovy (semaglutide 2.4 mg) and Mounjaro (tirzepatide), available via the electronic Medicines Compendium (emc) at medicines.org.uk/emc, provide detailed prescribing information and adverse event data for these licensed comparator therapies. Until retatrutide receives regulatory approval and NICE evaluation, clinicians and patients should rely on these established frameworks.

Anyone interested in accessing retatrutide should do so only through a registered clinical trial. Information on active UK trials can be found via the NHS Health Research Authority's Be Part of Research platform (bepartofresearch.nihr.ac.uk) or via ISRCTN.com and ClinicalTrials.gov. Self-sourcing unlicensed medicines outside of a regulated trial setting carries significant safety risks and is strongly discouraged.

Frequently Asked Questions